Your search for bevacizumab returned 3 results

The Agency could not approve the BLA due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.

The sBLA was based on efficacy and safety data from the KEYNOTE-A18 trial.

The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.